Kolexia
Mahe Beatrice Hématologie
Mahe Beatrice
Hématologie
Hôpital Hôtel-Dieu Nantes
Nantes, France
172 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie chronique lymphocytaire à cellules B Lymphomes Leucémie lymphoïde Macroglobulinémie de Waldenström Myélome multiple Maladie de Hodgkin Lymphome malin non hodgkinien Maladie résiduelle

Collaborateurs

Voir plus
Blin Nicolas
Blin Nicolas
Hôpital Hôtel-Dieu Nantes, Nantes, France
Dubruille Viviane
Dubruille Viviane
Hôpital Hôtel-Dieu Nantes, Nantes, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Gastinne Thomas
Gastinne Thomas
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
A+A
10 collaboration(s)
Dernière en 2022
Abbvie
4 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2023
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
American journal of hematology   02 janvier 2024
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia: Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Essai Clinique (University of Ulm)   29 novembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
HILDEGAZ: Phase 1 Dose Escalation of Early Infusion of Zoledronic Acid in Combination With Increasing Low-dose of Interleukin-2 in Order to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allogeneic Stem Cell Transplantation (SCT)
Essai Clinique (CHU Nantes)   05 octobre 2023
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
Essai Clinique (The Lymphoma Academic Research Organisation)   25 septembre 2023
RemodelWM3: An Open Label Non-randomized Phase II Study Exploring "Chemo-free " Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Essai Clinique (French Innovative Leukemia Organisation)   28 août 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood advances   28 juillet 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future oncology (London, England)   23 février 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   10 février 2023
A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
Annual Meeting Abstracts 2022   15 novembre 2022